New treatment option for the patients with advanced non-small-cell lung cancer

The study “Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis” shows that dacomitinib provides a new treatment option for the first-line treatment of patients with EGFRmutation-positive advanced non-small-cell lung cancer. Effective management of dacomitinib therapy can help to improve tolerability and patient experience of treatment-related symptoms, allowing patients to continue treatment (Future Oncol. 2019 May;15(13):1481-1491. doi: 10.2217/fon-2018-0944. Epub 2019 Mar 6).
 
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Tony Mok, Chairman of Our Department of Clinical Oncology. Prof Mok’s research focuses on biomarker and molecular targeted therapy in lung cancer. He is the co-founder of the Lung Cancer Research Group, and has led multiple multinational studies leading to the establishment of the global standard on personalized medicine for lung cancer.
 
Read the full article: https://www.futuremedicine.com/doi/full/10.2217/fon-2018-0944?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&
 
More about research at CU Medicine: https://research.med.cuhk.edu.hk